Submit an Article
Navigate
Home
Editorial Board
Editorial Policies
Current Volume
Archive
Scientific Integrity
Publication Ethics Statements
Interviews with Outstanding Authors
Newsroom
Sponsored Conferences
Podcast
Contact
Special Collections
Submit an Article
Online ISSN: 1945-4589
Research Paper
|
Volume 15, Issue 18
|
pp. 9779–9796
Pan-cancer analysis and experimental validation identify ndc1 as a potential immunological, prognostic and therapeutic biomarker in pancreatic cancer
Back to article
Figure 7
(7 of 11)
−
100%
+
Figure 7.
Correlation between NDC1 expression and IC50 of multiple anti-tumor drugs, including Chelerythrine, Allopurinol, 8-Chloro-adenosine, PX-316, Nelarabine, Parthenolide, 7-Tert-butyldimethylsilyl-10-hydroxycamptothecin and Elliptinium Acetate.
